NEW BRUNSWICK, N.J., April 17 /PRNewswire/ -- Big Pharma, typically reticent to take notice of anything other than blockbuster drug sales, are taking time to spin off relatively small-revenue or underperforming products to fledgling specialty start-ups. Once a sleepy sector in the public markets, specialty pharmaceuticals are now being covered by a growing number of stock analysts. More and more specialty pharmaceutical company business plans are showing up on the desks of VCs, and they are responding positively: the number of specialty pharmaceutical venture investments is growing at an enormous pace. The 2006 conference on specialty pharmaceuticals is an unprecedented opportunity for big pharma, biotech, specialty pharma, drug delivery companies & investment banks to learn, network and partner with the IR industry counterparts and access new information, announces Strategic Research Institute.
Full agenda: Tuesday, May 23, 2006 (Day 1) 7:30 AM Registration, Continental Breakfast & Exhibits 8:30 AM Chair’s Opening Remarks 8:40 AM Current Trends in Specialty Pharma Licensing and Deal Making Michael McCully Recombinant Capital Inc. 9:10 AM Assessing Value & Risk in Specialty Pharma Opportunities Craig Dees, Ph.D. Provectus Pharmaceuticals Inc. 9:40 AM Patent Protection for Controlled Release Products Clifford Davidson Davidson, Davidson & Kappel LLC 10:10 AM Networking Break & Exhibition 10:45 AM Specialty Pharma Awareness to Attract Big Pharma Portfolio Divestitures Moderator(s) Tim Saxon, MBA Pharma Consultant (Formerly of Wyeth) Panelist(s) Sabine Bernotat-Danielowski Daiichi Medical Research Teri Loxam Bristol-Myers Squibb Steven Kafka Millennium Pharmaceuticals Christine Fischette, Ph.D. Novartis Pharmaceuticals Corporation Adriann Sax King Pharmaceuticals 12:00 PM Specialty Pharma: Alliances Leading the Enterprise Harry Atkins, BSc, MBA Endo Pharmaceuticals 12:30 PM Luncheon 1:45 PM Portfolio and Pipeline Enhancement, Optimization & Strategies Seamus O’Loan Elan Pharmaceuticals 2:15 PM Therapeutic Area Specialization: What Does the Future Hold and What are the Unmet Areas for Lucrative Opportunities? Moderator(s) Vik Seoni Endo Pharmaceuticals Panelist(s) Woody Bryan Supernus Pharmaceuticals Inc. Christine Mayer Biovail Pharmaceuticals Richard Caroddo Integrium Suresh Borsdia Abeille Pharmaceuticals 3:15 PM Networking Break & Exhibition 3:45 PM Business Development Negotiation Strategies/Best Business Practices Christine Mayer Biovail Pharmaceuticals 4:15 PM Marketing Tools Fueling the Evolution of Specialty Pharma Business Development Ruth Mercado Nektar Therapeutics 4:45 PM Partnering in Specialty Pharma: A Novel & Profitable Business Model for the Pharmaceutical Industry Moderator(s) Howard Wachtler Actinium Pharmaceuticals, Inc Panelist(s) Michael McCully Recombinant Capital Inc. Craig Dees, Ph.D. Provectus Pharmaceuticals Inc. Anand Baichwal, Ph.D. Penwest Pharmaceuticals Michael Sheckler Javelin Pharmaceuticals 5:45 PM Networking Reception Wednesday, May 24, 2006 (Day 2) 7:30 AM Continental Breakfast & Exhibits 8:20 AM Chair’s Remarks 8:30 AM Product Conceptualization and Implementation in the Specialty Pharma Space Woody Bryan Supernus Pharmaceuticals Inc. 9:00 AM Avoiding Headaches and Nightmares of IP Issues in Specialty Pharma: Its Not as Simple as Taking an Aspirin Kathleen Williams Edwards Angell Palmer & Dodge LLP 9:30 AM What Do Venture Capitalists Want in a Specialty Pharma Investment & How Long Will They Continue to Invest? Moderator Bob Maggiacomo Synergy Advisors LLC Panelist(s) Todd Brady Domain Associates Stephen Hoffman Techno Venture Management Arthur Pappas A.M. Pappas & Associates 10:30 AM Networking & Exhibits 11:00 AM Specialization in Clinical Development - A Benefit for Specialty Pharma? Richard Caroddo Integrium Michael Miernicki Biovail 11:30 AM Prognosticating Pain Management: From Pipeline to Practitioner, the Drivers of Pain Compounds in Development and How They’ll be Delivered Michael Sheckler Javelin Pharmaceuticals 12:00 PM Specialty Drug Delivery Technologies for Life Cycle Management Jay Trivedi Patrin Pharma Inc. 12:30 PM Luncheon 1:45 PM From Biologicals to Biogenerics to Biospecialty Drugs: Opening Biotech Market to Generic & Specialty Companies Dragan Cicic Actinium Pharmaceuticals, Inc 2:15 PM Specialty Pharma Opportunities in Cancer Supportive Care: An In-Depth Look at Anti-Emetic Therapy Suresh Borsdia Abeille Pharmaceuticals 2:45 PM Value-Based Pricing and Reimbursement for Pharma & Biotech Products - Strategies for Specialty Pharma Sandip Shah Analytica International 3:15 PM Conference Concludes To register for the event, please visit http://www.srinstitute.com/cs385.
To receive the full agenda in PDF, please contact Ed Drilon of Strategic Research Institute at edrilon@srinstitute.com or 212-967-0095, x233 (please include name and corporate affiliation).
Leverage our strong position in the specialty pharma sector to showcase your products and services to this high-level, targeted audience of executive decision makers. To inquire about sponsorship & exhibition opportunities, please contact Mark Alexay at 212-967-0095 x251, malexay@srinstitute.com.
LUNCHEON SPEAKING OPPORTUNITIES FOR BOTH DAYS REMAIN AVAILABLE.
Strategic Research Institute
CONTACT: Ed Drilon of Strategic Research Institute, +1-212-967-0095, x233,edrilon@srinstitute.com, or Mark Alexay at +1-212-967-0095 x251,malexay@srinstitute.com, both of Strategic Research Institute
